AI in drug discovery is overhyped: examples from AstraZeneca, Harvard, Stanford and Insilico…

Investments in AI for drug discovery are surging. Big Pharmas are throwing big bucks. Sanofi signed a 300 Million dollars deal with the startup Exscientia, and GSK did the same for 42 Million dollars. The Silicon Valley VC firm Andreessen Horowitz launched a new 450 Million dollars bio investment fund, with one focus area in applications of AI to drug discovery. In this craze, lots of pharma/biotech companies and investors wonder whether they should jump on the bandwagon in 2018, or wait and see.